Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04990609 | EUS-RFA PANCARDINAL-1 Trial | recruiting | Phase 2 | 60 | The University of Texas Health Science Center, HoustonOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | recruiting | Phase 2 | 226 | AstraZenecaINDUSTRY | 14 | Jul 29, 2026 | clinicaltrials |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | recruiting | Phase 2 | 36 | Tiago Biachi de CastriaOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | recruiting | Phase 1 / Phase 2 | 160 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer(VIRAGE2) | recruiting | Phase 1 / Phase 2 | 6 | Theriva Biologics SLINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06796803 | Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | recruiting | Phase 2 / Phase 3 | 398 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06207305 | A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06478719 | To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization | recruiting | Phase 1 / Phase 2 | 120 | Febico Biomedical Corp.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07010497 | A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma(IAPETUS) | recruiting | Phase 2 | 33 | Asan Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05669339 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | recruiting | Phase 2 | 12 | University of FloridaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07018947 | Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC(ASPIRE) | recruiting | Phase 2 | 90 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 59 | Devalingam MahalingamOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | recruiting | Phase 1 / Phase 2 | 30 | Huahui HealthINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06986785 | A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 74 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07145801 | Y-90 Treatment Response Using Transarterial Radioembolization(TARE) | recruiting | Phase 2 | 30 | Thomas Jefferson UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07199764 | Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer(IGNITE) | recruiting | Phase 2 | 100 | University of PennsylvaniaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07226856 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | recruiting | Phase 2 | 43 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06790602 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma(SWITCH) | recruiting | Phase 2 | 43 | University of California, San DiegoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07483554 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | recruiting | Phase 2 | 389 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07483359 | Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus(CONV3RSION) | recruiting | Phase 2 | 38 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04982653 | Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2026source: clinicaltrials